Condition (MeSH)
Still's Disease, Adult-Onset
ClinicalTrials.gov lists 22 trials for Still's Disease, Adult-Onset or a narrower condition beneath it. Swedish Orphan Biovitrum has the most among industry and government lead sponsors, with 6.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
22 of the 22 trials are tagged with Still's Disease, Adult-Onset itself; the rest are tagged with a narrower condition beneath it.
When did Still's Disease, Adult-Onset trials start? (13)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 3 |
| 2023 | 3 |
| 2022 | 1 |
| 2021 | 2 |
| 2020 | 1 |
| 2018 | 3 |
| 2017 | 3 |
| 2015 | 1 |
| 2014 | 1 |
Showing 10 of 13 earlier years.
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 22 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Still's Disease, Adult-Onset trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 4 |
| Phase 3 | 4 |
| Phase 4 | 1 |
| Not applicable | 1 |
| Observational | 10 |
How many Still's Disease, Adult-Onset trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 5 |
| Active, not recruiting | 2 |
| Completed | 10 |
| Terminated | 2 |
| Withdrawn | 2 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Still's Disease, Adult-Onset trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Swedish Orphan Biovitrum | 6 |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 2 |
| Novartis Pharmaceuticals | 2 |
| AB2 Bio Ltd. | 1 |
| Apollo Therapeutics Ltd | 1 |
Showing 5 of 7 sponsors.
Which drugs are being tested for Still's Disease, Adult-Onset? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| RPH - 104 | 1 |
| Tadekinig alfa | 1 |
| Emapalumab | 1 |
| Rilonacept | 1 |
| Camoteskimab | 1 |
Interventions as named in the registry (6)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Anakinra alone (stages 2b/3) | 4 |
| add-on sirolimus therapy | 1 |
| data collection | 1 |
| Canakinumab, ACZ885 | 1 |
| comparators | 1 |
Showing 5 of 6 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Still's Disease, Adult-Onset trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Still's disease | 4 | 2 |
| Rash | 2 | 2 |
| Renal Calculi | 2 | 1 |
| Blood and lymphatic system disorders - Other (Macrophage Activation Syndrome) | 1 | 1 |
| COVID-19 | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Still's Disease, Adult-Onset? (24)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Efficacy and safety of emapalumab in macrophage activation syndrome. | Annals of the rheumatic diseases | 2023 | Yes |
| The administration of methotrexate in patients with Still's disease, "real-life" findings from AIDA Network Still Disease Registry. | Seminars in arthritis and rheumatism | 2023 | Yes |
| Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. | Annals of the rheumatic diseases | 2018 | Yes |
| Overview of fever of unknown origin in adult and paediatric patients. | Clinical and experimental rheumatology | 2018 | Yes |
| Benefit of Tocilizumab Therapy for Adult-Onset Still Disease Complicated With Acute Respiratory Distress Syndrome. | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases | 2016 | Yes |
Showing 5 of 24 publications.
Prevalence (24)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Adult-onset Still disease | Point prevalence | 1-9 / 100 000 | Norway | Not stated | Exact |
| Adult-onset Still disease | Point prevalence | 1-9 / 100 000 | Japan | Not stated | Exact |
| Adult-onset Still disease | Annual incidence | 1-9 / 1 000 000 | Turkey | Not stated | Unspecified |
| Adult-onset Still disease | Annual incidence | 1-9 / 1 000 000 | Japan | Not stated | Exact |
| Adult-onset Still disease | Point prevalence | 1-9 / 100 000 | Turkey | Not stated | Unspecified |
Showing 5 of 24 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Adult-onset Still disease | 829 | Exact | Orphadata Science knowledge files, Product 1 |
| Adult-onset Still disease | 829 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.